WEBULL
WebtradeDownload

Elan (TSE:6099) Q2 Results Contrast Revenue Growth And Profit Squeeze

Simply Wall St · 2d ago

Elan came into this Q2 2026 report with a solid reputation for steady compounding and a stock at ¥735 that screens as inexpensive on a 14.2x P/E. The headline this quarter is a profit squeeze. Basic earnings per share slipped to ¥13.03 and net income landed at ¥788.14m, both below Q1 levels even as revenue stayed near ¥14,762m. As a result, while the market has been slowly warming to Elan over the past month, the latest numbers challenge the easy thesis that this is just a cheap growth story on autopilot.

Impressed by Elan's low 14.2x P/E but uneasy about the recent profit squeeze against flat revenue. Explore peers that combine reasonable valuations with clearer earnings trends in our list of solid balance sheet and fundamentals stocks (21 results)

Q2 2026 Earnings Summary

  • Revenue (Q2 2026 vs Q2 2025): ¥14,762.01m vs. ¥13,406.45m (up about 10.1%)
  • Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): ¥788.14m vs. ¥566.98m (up about 39.0%)
  • Basic EPS (Q2 2026 vs Q2 2025): ¥13.03 vs. ¥9.38 (up about 39.0%)
  • Net Income Margin (Trailing 12 Months vs Prior Year): 5.4% vs. 4.7% (margin level higher over the last year)

Earnings give a quick snapshot, but investors who care about valuation tend to focus on the cash that actually comes through the door and how reliably it shows up year after year. Looking at Elan's cash flows and the assumptions behind them, the stock could be a clear 30% undervalued.

TSE:6099 Trailing 12-Month Revenue & Expenses Breakdown as at Nov 2026
TSE:6099 Trailing 12-Month Revenue & Expenses Breakdown as at Nov 2026

Elan earnings, where the bullish story still works

For the optimistic view on Elan, the core appeal is steady, healthcare linked services. The latest quarter still points that way. Revenue of ¥14,762.01m and basic EPS of ¥13.03 both sit clearly above Q2 2025 levels, and the trailing 12 month net margin is higher at 5.4% versus 4.7%. That pattern fits a patient, compounding style business. Recent 30 day share performance, up about 3%, suggests the market has been willing to give that stability some credit, even with a softer quarter on quarter earnings step.

Profit squeeze keeps the cautious Elan view alive

There is also enough in these figures to keep more cautious investors alert. Management delivered higher year on year revenue and EPS, yet net income in Q2 slipped against Q1 despite sales holding near ¥14,762m. That points to some pressure on profitability in the nearer term. The 90 day share price move, which is down about 4.7%, lines up with that more muted reading. The longer run margin trend looks better, but the latest quarterly step is a reminder this is not a risk free, autopilot earnings story.

With Elan reporting a softer profit performance compared with Q1 while investors focus on that 5.4% margin, it is important to verify whether liquidity, leverage and cash generation truly support the story. Analyze the financial health analysis of Elan stock

Hunt Quiet Dislocations Now

Elan’s latest numbers show how quickly sentiment can shift when profits feel tight. The real opportunity is spotting stocks that could be undervalued before the market closes the gap.

  • Company 1 - 32% below our estimate - runs payment rails that let merchants access card, bank, and wallet options.
  • Company 2 - 29% below our estimate - supplies motion components that equipment makers use to add precision in compact manufacturing lines.
  • Company 3 - 36% below our estimate - wins long term infrastructure and remediation work as public agencies refresh aging transport and civic assets.

Those are three of them. See the full list of 16 companies trading below our fair value estimates →